Tag: Portola Pharmaceuticals

Portola Pharmaceuticals unveils data on Andexxa in patients with multiple types...

Portola Pharmaceuticals announced new data that they say reinforces the value of Andexxa (coagulation factor Xa , inactivated-zhzo). The company statement outlines that the...

Interim results from ongoing ANNEXA-4 study of Factor Xa inhibitor reversal...

Interim data from 228 patients (of which 132 were adjudicated for efficacy) showed that AndexXa rapidly and significantly reversed anti-Factor Xa activity (the anticoagulant...

US FDA accepts Biologics License Application resubmission of reversal agent andexanet...

Portola Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has found its resubmitted Biologics License Application andexanet alfa (AndexXa) to be...

Bristol-Myers Squibb and Pfizer provide US$50 million dollar loan to Portola...

Portola Pharmaceuticals has signed a US$50 million loan agreement with Bristol-Myers Squibb and Pfizer that provides additional funding toward development and clinical studies of...

Andexanet alfa study shows rapid and substantial anti-Factor Xa activity reversion

Portola Pharmaceuticals has announced interim results from the ongoing phase3b/4 ANNEXA-4 study of andexanet alfa (AndexXa), a Factor Xa inhibitor antidote. In this study of...